{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NRIX",
  "name": "Nurix Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/NRIX/",
  "json_url": "https://frontierpicks.com/dossiers/NRIX.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Roche-partnered BTK degrader moved from validation to execution: first patient in the registrational Phase 3 DAYBreak CLL-306 on 2026-08-04, RBC to $36 on 2026-08-10, price to a new 52-week high on 2026-08-14. Narrative still accelerating, but RSI(14) 81.3 into a catalyst vacuum — the next bexobrutideg efficacy dataset is ASH ~December.",
  "invalidation_trigger": "A weekly close below $24 surrenders the post-Roche re-rating and the June breakout shelf that carried the $31–40 target cluster; secondary: the 2026-09-09/12 SOHO window passing with no bexobrutideg dataset, leaving the RSI-81 extension in a vacuum until ASH ~December.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends November 30 — the 'Q2 2026' print on 2026-07-09 covers the quarter ended May 31; reporting labels do not map to calendar quarters.",
    "Collaboration and milestone revenue is partner-timed and lumpy; a quarterly revenue 'miss' headline is largely timing, while the equity trades on bexobrutideg CLL data.",
    "Value concentrates in one asset. Gilead, Sanofi, Pfizer and Roche deals carry milestone optionality, but CLL outcomes set the equity.",
    "Phase 3 DAYBreak CLL-306 is a randomized ~620-patient registrational trial — its primary readout is a multi-year event, not a 2026 one.",
    "Sell-side coverage is one-directional (targets $31–40, no dated downgrade 2026-06-15 to 2026-08-10); further raises are confirmation of a move already made."
  ],
  "body_markdown": "## Current Thesis\n\nThe leg on offer has changed character twice in five weeks. On 2026-07-21 Roche finalized the bexobrutideg (NX-5948) co-development collaboration — $700M upfront, up to $2.3B with milestones, Roche carrying 60% of clinical development cost against Nurix's 40% — which converted a single-asset clinical story into a partnered one. On 2026-08-04 the same asset moved from validation to execution: first patient enrolled in the registrational Phase 3 DAYBreak CLL-306 trial in relapsed/refractory CLL/SLL, a randomized study sized at roughly 620 patients and run under the Roche collaboration. The same morning, Sanofi's initiation of a Phase 1 study of SAR448272/NX-3911, an oral STAT6 degrader, triggered a $10M milestone, bringing total receipts under the 2019 Sanofi partnership to approximately $139M. RBC raised its target to $36 on 2026-08-10. Price closed 2026-08-14 at $27.05, within 0.5% of the $27.19 52-week high, +70.6% over three months, RSI(14) 81.3.\n\nThe narrative is intact and still adding dated facts. What it does not have is a near-term data event. The Phase 3 is an enrollment story for years; the next bexobrutideg efficacy dataset of consequence is CLL durability at ASH, expected around December. An investor buying here is buying a partnered registrational program at a new high, into a stretch of calendar where nothing clinical resolves.\n\n## Bull Case\n\n- **Registrational trial is running (2026-08-04).** First patient enrolled in Phase 3 DAYBreak CLL-306, ~620 patients, randomized, R/R CLL/SLL — the first Phase 3 for bexobrutideg and the step that converts a Phase 1a/b dataset into a registration path.\n- **Roche is funding 60% of that spend (2026-07-21).** $700M upfront, up to $2.3B with milestones, 60/40 clinical-cost split. For a company that reported $9.043M of quarterly revenue on 2026-07-09, the deal is the runway, not a rounding item.\n- **Second partner produced cash in the same window (2026-08-04).** Sanofi's Phase 1 start of SAR448272/NX-3911 (STAT6 degrader) triggered $10M; cumulative receipts under the 2019 Sanofi agreement are approximately $139M. The DELigase platform pays independent of CLL.\n- **Degradation is aimed at the resistance problem (EHA 2026, Stockholm, June 11–14).** Updated Phase 1a/b CLL efficacy and safety went to an oral session; the pitch is activity in patients who progressed on covalent and non-covalent BTK inhibitors, where C481S/L528W mutations blunt inhibitors but not degraders.\n- **Sell-side has not backed off.** RBC to $36 (2026-08-10) and Needham reiterating $34 (2026-08-04) came after the Phase 3 headline, extending a band that runs $31 (UBS, 2026-07-22) to $40 (Stifel, 2026-07-10). The 2026-08-14 close of $27.05 sits under the entire live target band.\n\n## Bear Case\n\n- **The August news was structural, not efficacy.** A first-patient-enrolled announcement contains no response data. Between 2026-08-04 and ASH (~December), the clinical file does not update, and a name at RSI 81.3 has to hold a new high on flow alone.\n- **Two overbought readings, not one.** NRIX was named in a 2026-06-30 RSI screen alongside DFTX and GALT; six weeks later RSI(14) reads 81.3 with price 0.5% off the 52-week high after a +70.6% three-month run.\n- **Phase 3 duration is the cost of the upgrade.** A ~620-patient randomized registrational trial in R/R CLL reads out on a multi-year clock. Enrollment-progress releases are the near-term newsflow.\n- **Revenue is partner-timed and missed badly last print (2026-07-09).** Q2 sales $9.043M against $16.170M consensus, a 44% shortfall; EPS $(0.81) versus $(0.74). Lumpy by construction, but it keeps burn and milestone-timing in the frame.\n- **The competitive readout risk is on the same calendar.** BeiGene's BGB-16673 and other BTK degraders chase the same double-refractory CLL population and present into the same congresses; a stronger competitor dataset re-rates the whole comparison set.\n- **Analyst positioning is one-directional.** No dated downgrade or target cut appears in the 2026-06-15 to 2026-08-10 window. Incremental raises into a new high are confirmation of what has happened.\n\n## Setup & Price Structure\n\nThe narrative is **accelerating**, dated by the 2026-08-04 Phase 3 first-patient-in plus the $10M Sanofi milestone, the 2026-08-10 RBC raise to $36, and the 2026-08-14 close of $27.05 marking a new 52-week high at $27.19. New corporate facts are still arriving and price is making highs on them.\n\nThe crowding evidence — stated as observables, not as a verdict:\n- RSI(14) 81.3 as of 2026-08-14, the second overbought condition since the 2026-06-30 momentum screen that named NRIX with DFTX and GALT.\n- Price within 0.5% of the 52-week high after +70.6% over three months.\n- Nine-plus Buy/Outperform actions clustered 2026-06-15 through 2026-08-10 with targets $31–40 and no dated bearish action in the window; price now sits below the lowest of those targets, so the gap the sell-side is underwriting has narrowed since June.\n- No insider transactions or equity-issuance filings appear in the filing record reviewed for this update; that is an absence of evidence rather than evidence of absence.\n- No earnings print is imminent — the fiscal quarter ends 2026-08-31 and the prior-year Q3 release landed 2025-10-09.\n\nStructurally, the levels that matter are the ones the last two catalysts created. The June breakout shelf sits in the low-$20s; the post-Roche re-rating from 2026-07-21 and the 2026-08-04 Phase 3 gap stack above it. A weekly close under $24 puts price back beneath both events, which is the condition under which the re-rating stops being a base and starts being a round trip. The narrative would flip toward saturated if the next incremental headlines are target raises and conference-attendance notices rather than patient data.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-09 to 2026-09-12 — SOHO 2026 Annual Meeting, George R. Brown Convention Center, Houston.** Nurix presented encore Phase 1 Waldenström macroglobulinemia data for bexobrutideg at SOHO 2025. Company participation in 2026 is not confirmed as of 2026-08-16; this is a dated venue, not a company-confirmed event.\n- **~2026-10-08 (est.) — Q3 FY2026 results.** Fiscal quarter ends 2026-08-31; the prior-year Q3 release was 2025-10-09. First print to show the $700M Roche upfront and the 60/40 cost split in the accounts. Outside the 30-day window.\n- **~2026-11 (est.) — ASH 2026 abstract titles.** Historically released in early November; the first indication of what bexobrutideg CLL data is being brought forward.\n- **~2026-12 (est.) — ASH 2026 annual meeting.** Bexobrutideg CLL durability is the next dataset with the weight to move the asset.\n\nNo company-confirmed dated clinical catalyst falls inside the next 30 days as of 2026-08-16.\n\n## What Would Change Our Mind\n\nThe structure breaks if the two events that built the current high stop holding price. Losing the post-Roche re-rating and the June breakout shelf together — a weekly close below $24 — would mean the market has repriced the partnership and the Phase 3 start back to pre-deal terms, which is a different security from the one described above.\n\nSecond, the calendar can invalidate by elapsing. If the 2026-09-09/12 SOHO window passes with no bexobrutideg dataset and the only new items through the Q3 print are target adjustments, the name is holding an RSI-81 extension through a pure vacuum, and the accelerating label no longer fits.\n\nThird, on the fundamentals: a Q3 FY2026 print in early October showing a second consecutive collaboration-revenue shortfall, or any disclosure that the Roche collaboration's scope or cost-share has been altered, would break the funded-registrational-program frame directly rather than through price. On the other side, a dated Phase 3 enrollment-completion or interim-analysis timeline that pulls the readout closer than the current multi-year expectation would strengthen the case at whatever price it arrives.\n\n## Correlation Notes\n\n- **Small-cap biotech beta.** A pre-revenue clinical name with a +70.6% three-month move trades with XBI-style risk appetite and rate expectations; a broad biotech drawdown hits the extended names hardest regardless of the Roche cash.\n- **Targeted-protein-degradation complex.** Kymera, C4 Therapeutics and Arvinas move on the same modality headlines; a safety or efficacy problem in any high-profile degrader can compress the group's multiple.\n- **Direct BTK-degrader comparison.** BeiGene's BGB-16673 is the closest read-across in double-refractory CLL; its congress datasets are effectively a relative-value input for bexobrutideg.\n- **CLL incumbents.** AbbVie/J&J covalent BTK inhibitors, BeiGene's Brukinsa and Lilly's pirtobrutinib define the standard of care the Phase 3 has to beat; a label expansion or durability update on any of them shifts the bar.\n- **Congress clustering.** EHA (June), SOHO (September) and ASH (December) concentrate the sector's information into three windows, so the degrader names tend to move together on the same dates rather than idiosyncratically.\n- **Roche as counterparty.** Partner capital-allocation decisions and any change in Roche's hematology priorities transmit directly to the 60/40 cost structure funding the Phase 3.",
  "first_seen": "2026-07-07",
  "last_analyzed": "2026-08-16T15:42:20+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}